Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 41.5 | 48.7 | 59.3 | 60.1 | 64.2 | 64.9 | 67.3 | 67.2 |
| Operating profit | $bn | 23.5 | 10.9 | ||||||
| Net profit | $bn | 7.1 | 13.0 | 14.5 | 0.4 | 17.1 | 18.3 | - | 6.9 |
| EPS reported | $ | 7.28 | - | ||||||
| Operating cashflow per share | $ | 6.58 | 7.55 | ||||||
| Capex per share | $ | 1.64 | 1.60 | ||||||
| FCF per share | $ | 4.94 | 5.95 | ||||||
| Free cash flow | $bn | 12.4 | 14.7 | ||||||
| Net debt | $bn | 35.1 | 44.1 | ||||||
| Book value equity | $bn | 52.6 | 44.9 | ||||||
| Book value per share | $ | 20.98 | 18.12 | ||||||
| Number of shares | m | 2,507 | 2,478 | ||||||
| DPS (TTM paid) | $ | 3.28 | 3.40 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 14.46 | 151.74 | ||||||
| P/B LTM | x | 5.01 | 8.08 | ||||||
| P/S LTM | x | 4.06 | 5.39 | ||||||
| P/FCF LTM | x | 21.31 | 24.61 | ||||||
| EV/EBITDA LTM | x | 10.59 | 31.23 | ||||||
| EV/Sales LTM | x | 4.61 | 6.05 | ||||||
| Earnings Yield LTM | % | 6.92% | 0.66% | ||||||
| FCF Yield | % | 4.69% | 4.06% | ||||||
| Quality | |||||||||
| ROE | % | 34.70% | 5.29% | ||||||
| ROIC | % | 18.27% | 5.20% | ||||||
| Operating margin | % | 36.17% | 16.24% | ||||||
| Gross margin | % | 71.98% | 76.95% | ||||||
| FCF/Sales | % | 19.04% | 21.91% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +8.01% | - | ||||||
| Sales Growth YoY | % | +1.18% | +4.79% | ||||||
| Net Income Growth YoY | % | +6.64% | - | ||||||
| FCF Growth | % | -31.70% | +13.00% | ||||||
| Operating Profit Growth | % | +16.15% | -56.08% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 3.10% | 2.31% | ||||||
| Dividend Growth | % | +5.13% | +4.94% | ||||||
| Payout Ratio | % | 44.80% | 44.79% | ||||||
| FCF/Debt | x | 0.24 | 0.27 | ||||||
| Net Debt/EBITDA | x | 1.27 | 3.39 | ||||||
| EBIT/Net interest | x | 17.31 | 11.67 | ||||||
| Net debt/market cap | % | 13.32% | 12.16% | ||||||
| Net debt/Equity | x | 0.67 | 0.98 | ||||||
| Gross debt/equity | x | 0.96 | 1.20 | ||||||
ETFs that hold Merck
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Vanguard High Dividend Yield ETF | VYM | 9 | 1.52% |
| iShares S&P 500 Value ETF | IVE | 9 | 1.21% |
| State Street Health Care Select Sector SPDR ETF | XLV | 4 | 5.41% |
| State Street SPDR Portfolio S&P 500 Value ETF | SPYV | 9 | 1.21% |
| iShares Core S&P U.S. Value ETF | IUSV | 9 | 1.14% |
| iShares MSCI USA Min Vol Factor ETF | USMV | 9 | 1.44% |
| Invesco S&P 500 Momentum ETF | SPMO | 9 | 2.68% |
| Vanguard Health Care ETF | VHT | 4 | 5.01% |
| Vanguard FTSE All-World High Dividend Yield UCITS ETF (USD) Distributing | VHYL.L | 8 | 0.83% |
| Vanguard S&P 500 Value ETF | VOOV | 9 | 1.23% |
Funds with Merck among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Vanguard High Dividend Yield ETF | VYM | 9 | 1.52% |
| iShares S&P 500 Value ETF | IVE | 9 | 1.21% |
| State Street Health Care Select Sector SPDR ETF | XLV | 4 | 5.41% |
| State Street SPDR Portfolio S&P 500 Value ETF | SPYV | 9 | 1.21% |
| iShares Core S&P U.S. Value ETF | IUSV | 9 | 1.14% |
| iShares MSCI USA Min Vol Factor ETF | USMV | 9 | 1.44% |
| Invesco S&P 500 Momentum ETF | SPMO | 9 | 2.68% |
| Vanguard Health Care ETF | VHT | 4 | 5.01% |
| Vanguard FTSE All-World High Dividend Yield UCITS ETF (USD) Distributing | VHYL.L | 8 | 0.83% |
| Vanguard S&P 500 Value ETF | VOOV | 9 | 1.23% |
Funds with Merck among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free